Lymphoma & Myeloma 2015 Congress Offers Research And Translational Medicine Updates

Lymphoma & Myeloma 2015 Congress Offers Research And Translational Medicine Updates
0
(0)

This year’s much-awaited Lymphoma & Myeloma 2015: An International Congress on Hematologic Malignancies is set to take place on October 22 to 24 at the Waldorf Astoria in New York as a premier event for the latest updates on lymphoma, myeloma, chronic lymphocytic leukemia, Waldenström’s macroglobulinemia and other plasma cell neoplasms.

“This is the premier meeting for clinicians in these specialties,” congress chair Morton Coleman, MD, director of the Center for Lymphoma and Myeloma at NewYork Presbyterian Hospital-Weill Cornell Medical Center and clinical professor of medicine at Weill Cornell Medical College, told HemOnc Today. “The common refrain I hear from attendees is, ‘I don’t need to go to ASH or ASCO anymore and run from room to room. You have everything right here for us in one place.”

“When you walk out of here, you’re as up to date as you can possibly be,” Coleman said. “We cover everything.”

The congress’ program also features lectures on immunological approaches to treat Hodgkin’s disease, and the use of signalling inhibitors to address chronic lymphocytic leukemia. One of the scheduled presentations on myeloma will wrap up with a debate on the role HDAC inhibitors now play among treatment options for the disease, and if it is a toxic alternative.

The conference expects over a thousand attendees, including 40 of the most prominent leaders in clinical and translational research, pathology, immunology and molecular biology. “The faculty is second to none,” Coleman said. “I vet the faculty not only for their expertise, but for their ability to present. The quality is just outstanding. We have all the heavyweights in these fields — you name them, they’ll be there.”

To know more about the congress and for a list of key faculty members for the event, call (800) 233-0957 or go to www.imedex.com/lymphoma-myeloma-conference/index.asp

Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
×
Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Latest Posts
  • ATG-019 Phase 1 trial
  • ME-401, FDA fast track
  • Tafasitamab combo, lymphoma
  • blood biomarkers

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?